GlassScriptPhysician profile
Wei William Bao
NPI 1437199304
$72,254.69
in general payments reported to CMS, 2019-2025
36 companies · $5,788 in 2025
The $5,788 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $3,250 · 2021: $8,526 · 2022: $9,488 · 2023: $9,805 · 2024: $15K · 2025: $5,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,990 · Consulting Fee: $3,130 · Travel and Lodging: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,390.00 |
| Food and Beverage | $6,989.96 |
| Consulting Fee | $3,130.00 |
| Travel and Lodging | $1,626.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58,171.06 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $3,070.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,385.12 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,347.73 | 2019-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $1,097.30 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Esperion Therapeutics, INC. | $836.77 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $583.43 | 2019-2022 | |
| Astellas Pharma US INC | $570.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $479.40 | 2019-2025 | |
| Amarin Pharma, INC. | $478.87 | 2019-2022 | |
| Lilly USA, LLC | $460.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $457.99 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $356.00 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $344.42 | 2019-2022 | |
| Glaxosmithkline, LLC. | $303.19 | 2019-2024 | Trelegy Ellipta, Arexvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $272.39 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.16 | 2019-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $123.64 | 2023-2024 | Inpefa |
| Vivus LLC | $85.08 | 2022-2025 | Pancreaze |
| Abbvie INC. | $77.01 | 2019-2023 | Linzess, Creon |
| Sanofi-Aventis U.S. LLC | $69.20 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $65.40 | 2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $62.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $60.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $59.25 | 2021-2022 | |
| Edwards Lifesciences Corporation | $37.91 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Eisai INC. | $35.10 | 2021 | |
| Dexcom, INC. | $34.70 | 2023 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $20.99 | 2021 | |
| Ironwood Pharmaceuticals, INC | $20.06 | 2021 | |
| Alvogen INC | $19.48 | 2022 | |
| Pfizer INC. | $18.31 | 2019 | |
| Avanos Medical | $16.14 | 2023 | Trivisc Sodium Hyaluronate |
| Allergan, INC. | $13.85 | 2019 | |
| Aytu Biopharma, INC. | $12.41 | 2019 | |
| Genentech USA, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Bao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.